parecoxib has been researched along with etomidate in 1 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (etomidate) | Trials (etomidate) | Recent Studies (post-2010) (etomidate) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 2,071 | 401 | 576 |
| Protein | Taxonomy | parecoxib (IC50) | etomidate (IC50) |
|---|---|---|---|
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.0005 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.0009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X; Liu, J; Zhou, C; Zhou, M | 1 |
1 trial(s) available for parecoxib and etomidate
| Article | Year |
|---|---|
Parecoxib sodium pretreatment reduces myoclonus after etomidate: A prospective, double-blind, randomized clinical trial
.
Topics: Administration, Intravenous; Adult; Anesthesia, General; Anesthetics, Intravenous; China; Cholecystectomy, Laparoscopic; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Etomidate; Female; Humans; Isoxazoles; Male; Middle Aged; Myoclonus; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2017 |